Sage Therapeutics Inc (NASDAQ: SAGE) stock suffered a major decline of -19.6% on 4/17/24. The shares closed at $12.57. Moreover, trading volume in this decline was exceptionally high at 420% of normal. The stock has been weak relative to the market over the last nine months and has declined -23.9% during the last week.
Current PriceTarget Research Rating
SAGE’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Sage Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Sage Therapeutics has a poor Appreciation Score of 20 and a poor Power Rating of 20, producing the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment